| |
Global Distribution & Prevalence of HCV Genotypes
|
| |
| |
......"The data presented here represent the most comprehensive effort to date to estimate the relative contribution of each HCV genotype to the global HCV epidemic.".......http://www.natap.org/2014/HCV/073014_03.htm........
Genotypes in USA state by state, Labcorp report:
http://www.natap.org/2015/HCV/LabCorp+Virology+Report+Hepatitis+C+Virus.pdf
Genotype Numbers in USA - (06/15/15)
Also in development are 3 additional pangenotypic regimens: 2nd/3rd generation regimens - Abbvie ABT493+ABT530 just finished up phase 3, Merck's triple MK8408+MK3682+grazoprevir is planning for phase 3, and J&J reported early data on its triple at EASL ACH-3102 + simeprevir + AL-335 & just started phase 2....And Gilead is in phase 3 with a triple regimen Sofosbuvir/velpatasvir+GS-9857......
Newest HCV Drugs at EASL - (05/03/16)
AASLD: Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (12/11/15)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.....http://www.natap.org/2015/AASLD/AASLD_67.htm
High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials (12/14/15)
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia. Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%. While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions ofgenotypes 4 and 5 are in lower-income countries. Conclusion: Although genotype 1 is most common worldwide, nongenotype 1 HCV cases-which are less well served by advances in vaccine and drug development-still comprise over half of all HCV cases. Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments. Genotype surveillance data are needed from many countries to improve estimates of unmet need.
"In North America, genotype 1a predominates, followed by genotypes 1b, 2a, 2b, and 3a. In Europe, genotype 1b is predominant, followed by genotypes 2a, 2b, 2c, and 3a. Genotypes 4 and 5 are found almost exclusively in Africa
|
|
| |
| |
|
|
|
